Phaseline

Targets › TOPO2

TOPO2: drug programs, companies and trials

2 programs from 1 company in 4 trials: 3 Phase 2, 1 Phase 3; Oncology; next expected readout Feb 2027.

Open in Phaseline: the race on TOPO2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Centre Hospitalier Universitaire Dijonmodified FOLFOX
Multi-drug chemotherapy: folate antagonist (folinic acid), thymidylate synthase inhibitor
TOPO2, TYMS, DHFR, SLC22A16Phase 3Colon Cancer; Locally Advanced or Metastatic Small Bowel AdenocarcinomaFeb 2027
Centre Hospitalier Universitaire DijonFOLFOXIRI Protocol (modified FOLFIRINOX)
Combination chemotherapy: irinotecan (TOPO1 inhibitor) + oxaliplatin (TOPO2 inhibitor) + f
TOPO1, TOPO2, TYMSPhase 2Locally Advanced or Metastatic Small Bowel Adenocarcinoma; Neuroendocrine CarcinomaFeb 2027

Conditions

Locally Advanced or Metastatic Small Bowel Adenocarcinoma (2) Neuroendocrine Carcinoma (1) Colon Cancer (1)

Modalities

small molecule (2)

Companies

Centre Hospitalier Universitaire Dijon (2)

Related targets

TYMS (2) TOPO1 (1) DHFR (1) SLC22A16 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.